Cargando…

Mechanisms of Cisplatin-Induced Apoptosis and of Cisplatin Sensitivity: Potential of BIN1 to Act as a Potent Predictor of Cisplatin Sensitivity in Gastric Cancer Treatment

Cisplatin is the most important and efficacious chemotherapeutic agent for the treatment of advanced gastric cancer. Cisplatin forms inter- and intrastrand crosslinked DNA adducts and its cytotoxicity is mediated by propagation of DNA damage recognition signals to downstream pathways involving ATR,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tanida, Satoshi, Mizoshita, Tsutomu, Ozeki, Keiji, Tsukamoto, Hironobu, Kamiya, Takeshi, Kataoka, Hiromi, Sakamuro, Daitoku, Joh, Takashi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2012
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3384945/ https://www.ncbi.nlm.nih.gov/pubmed/22778941 http://dx.doi.org/10.1155/2012/862879

Ejemplares similares

Managing refractory Crohn’s disease: challenges and solutions
por: Tanida, Satoshi, et al.
Publicado: (2015)

Combination Therapy with Intensive Granulocyte and Monocyte Adsorptive Apheresis plus Adalimumab: Therapeutic Outcomes in 5 Cases with Refractory Crohn's Disease
por: Ozeki, Keiji, et al.
Publicado: (2012)

The First Case of Biological Therapy Discontinuation After a Complete Remission Induced by Maintenance Therapy With Adalimumab for Refractory Ulcerative Colitis
por: Tanida, Satoshi, et al.
Publicado: (2015)

Anti-cancer effects of newly developed chemotherapeutic agent, glycoconjugated palladium (II) complex, against cisplatin-resistant gastric cancer cells
por: Tanaka, Mamoru, et al.
Publicado: (2013)

Colon Mucosa Exhibits Loss of Ectopic MUC5AC Expression in Patients with Ulcerative Colitis Treated with Oral Tacrolimus
por: Mizoshita, Tsutomu, et al.
Publicado: (2013)

Adalimumab Treatment in Biologically Naïve Crohn's Disease: Relationship with Ectopic MUC5AC Expression and Endoscopic Improvement
por: Mizoshita, Tsutomu, et al.
Publicado: (2014)

Combination Therapy With Adalimumab Plus Intensive Granulocyte and Monocyte Adsorptive Apheresis in Patients With Refractory Ulcerative Colitis
por: Tanida, Satoshi, et al.
Publicado: (2015)

Telmisartan Inhibits Cell Proliferation by Blocking Nuclear Translocation of ProHB-EGF C-Terminal Fragment in Colon Cancer Cells
por: Ozeki, Keiji, et al.
Publicado: (2013)

Long-Term Efficacy of Adalimumab in Patients With Intestinal Behcet’s Disease: Eight Consecutive Cases
por: Tanida, Satoshi, et al.
Publicado: (2016)

Long-Term Clinical Remission in Biologically Naïve Crohn's Disease Patients with Adalimumab Therapy, Including Analyses of Switch from Adalimumab to Infliximab
por: Mizoshita, Tsutomu, et al.
Publicado: (2016)

Organizing Pneumonia in a Patient with Quiescent Crohn's Disease
por: Tanida, Satoshi, et al.
Publicado: (2016)

New Synthetic Lethality Re-Sensitizing Platinum-Refractory Cancer Cells to Cisplatin In Vitro: The Rationale to Co-Use PARP and ATM Inhibitors
por: Folk, Watson P., et al.
Publicado: (2021)

Therapeutic Effects of Biobran, Modified Arabinoxylan Rice Bran, in Improving Symptoms of Diarrhea Predominant or Mixed Type Irritable Bowel Syndrome: A Pilot, Randomized Controlled Study
por: Kamiya, Takeshi, et al.
Publicado: (2014)

Involvement of oxidative stress and mucosal addressin cell adhesion molecule-1 (MAdCAM-1) in inflammatory bowel disease
por: Tanida, Satoshi, et al.
Publicado: (2011)

Prospective comparison of preference and efficacy of adalimumab and infliximab for treating ulcerative colitis naive to antitumor necrosis factor therapy
por: Mizoshita, Tsutomu, et al.
Publicado: (2017)

Combination therapy with cisplatin and nifedipine induces apoptosis in cisplatin-sensitive and cisplatin-resistant human glioblastoma cells.
por: Kondo, S., et al.
Publicado: (1995)

A Complicated Case of Tacrolimus-Induced Rapid Remission after Cesarean Section in the Early Third Trimester for Refractory Severe Ulcerative Colitis Flaring in the Initial Period of Gestation
por: Mizushima, Takashi, et al.
Publicado: (2011)

Mechanism of hyperthermic potentiation of cisplatin action in cisplatin-sensitive and -resistant tumour cells.
por: Hettinga, J. V., et al.
Publicado: (1997)

Hymenialdisine is Cytotoxic Against Cisplatin-Sensitive but Not Against Cisplatin-Resistant Cell Lines
por: Abdullah, Nada, et al.
Publicado: (2021)

Cisplatin-resistant HepG2 cell-derived exosomes transfer cisplatin resistance to cisplatin-sensitive cells in HCC
por: Tang, Zuxiong, et al.
Publicado: (2021)

Platinum sensitivity and non-cross-resistance of cisplatin analogue with cisplatin in recurrent cervical cancer
por: Takekuma, Munetaka, et al.
Publicado: (2015)

Combination Therapy With Tofacitinib Plus Intensive Granulocyte and Monocyte Adsorptive Apheresis as Induction Therapy for Refractory Ulcerative Colitis
por: Tanida, Satoshi, et al.
Publicado: (2020)

lncRNAs are novel biomarkers for differentiating between cisplatin-resistant and cisplatin-sensitive ovarian cancer
por: Li, Qing, et al.
Publicado: (2018)

Identification of solamargine as a cisplatin sensitizer through phenotypical screening in cisplatin-resistant NSCLC organoids
por: Han, Yi, et al.
Publicado: (2022)

Nuclear translocation of the cytoplasmic domain of HB-EGF induces gastric cancer invasion
por: Shimura, Takaya, et al.
Publicado: (2012)

A multicenter randomized trial comparing rabeprazole and itopride in patients with functional dyspepsia in Japan: the NAGOYA study
por: Kamiya, Takeshi, et al.
Publicado: (2017)

Cisplatin anti-tumour potentiation by tirapazamine results from a hypoxia-dependent cellular sensitization to cisplatin
por: Kovacs, M S, et al.
Publicado: (1999)

Metformin combined with p38 MAPK inhibitor improves cisplatin sensitivity in cisplatin-resistant ovarian cancer
por: XIE, YA, et al.
Publicado: (2014)

A Strategy to Delay the Development of Cisplatin Resistance by Maintaining a Certain Amount of Cisplatin-Sensitive Cells
por: Duan, Guihua, et al.
Publicado: (2017)

Ascorbate sensitizes human osteosarcoma cells to the cytostatic effects of cisplatin
por: Oka, Naohiro, et al.
Publicado: (2020)

Expression and subcellular localization of AT motif binding factor 1 in colon tumours
por: Kataoka, Hiromi, et al.
Publicado: (2017)

Changes in 12-Year First-Line Eradication Rate of Helicobacter pylori Based on Triple Therapy with Proton Pump Inhibitor, Amoxicillin and Clarithromycin
por: Sasaki, Makoto, et al.
Publicado: (2010)

Prodigiosin Sensitizes Sensitive and Resistant Urothelial Carcinoma Cells to Cisplatin Treatment
por: Berning, Lena, et al.
Publicado: (2021)

Sensitization of ovarian cancer cells to cisplatin by gold nanoparticles
por: Xiong, Xunhao, et al.
Publicado: (2014)

NVP-BEZ235 synergizes cisplatin sensitivity in osteosarcoma
por: Huang, Jin-Cheng, et al.
Publicado: (2017)

Cisplatin resistance coupled to enhanced sensitivity to metabolic interventions
por: Castedo, Maria, et al.
Publicado: (2018)

Novel Expression of EGFL7 in Osteosarcoma and Sensitivity to Cisplatin
por: Liu, Qing, et al.
Publicado: (2020)

Hsp90 inhibition sensitizes DLBCL cells to cisplatin
por: Schmidt, Linnéa, et al.
Publicado: (2022)

EGCG Enhances Cisplatin Sensitivity by Regulating Expression of the Copper and Cisplatin Influx Transporter CTR1 in Ovary Cancer
por: Wang, Xuemin, et al.
Publicado: (2015)

Efficacy of HDAC Inhibitors Belinostat and Panobinostat against Cisplatin-Sensitive and Cisplatin-Resistant Testicular Germ Cell Tumors
por: Lobo, João, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_ppathc88kurk3aft3jppm5h53v